(Q33487314)

27 July 2017

title

High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients (English)

1 reference

27 July 2017

0 references

E A Wilson

1

1 reference

27 July 2017

G J Sills

series ordinal

2

1 reference

27 July 2017

G Forrest

series ordinal

3

1 reference

27 July 2017

M J Brodie

series ordinal

4

1 reference

27 July 2017

publication date

1 January 1998

1 reference

27 July 2017

1 reference

27 July 2017

volume

29

1 reference

27 July 2017

issue

2

1 reference

27 July 2017

page(s)

161-166

1 reference

Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

New antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

Determination of gabapentin in plasma by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

Behavioral side effects of gabapentin in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

Five years of anticonvulsant monitoring on site at the epilepsy clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

1 reference

7 January 2021

The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

Gabapentin toxicity in children manifesting as behavioral changes.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2897%2900078-8

7 January 2021

10.1016/S0920-1211(97)00078-8

Identifiers

DOI

1 reference

27 July 2017

1 reference